Value and usability of unpublished data sources for systematic reviews and network meta-analyses

Nicholas James Anthony Halfpenny, Joan Mary Quigley, Juliette Catherine Thompson, David Alexander Scott

Abstract

Peer-reviewed publications and conference proceedings are the mainstay of data sources for systematic reviews and network meta-analyses (NMA), but access to informative unpublished data is now becoming commonplace. To explore the usefulness of three types of ‘grey’ literature—clinical trials registries, clinical study reports and data from regulatory authorities—we conducted four case studies. The reporting of outcome data in peer-reviewed publications, the clinical trials registries and the clinical study reports for two clinical trials—one in melanoma, one in juvenile idiopathic arthritis (JIA)—was examined. In addition, we assessed the value of including unpublished data from the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) in evidence syntheses of hepatitis C virus (HCV) and chronic obstructive pulmonary disease (COPD), respectively. For the clinical trials in melanoma and JIA, we identified outcome parameters on ClinicalTrials.gov additional to those reported in the peer-reviewed publications: subgroup data and additional efficacy end points/extended follow-up, respectively. The clinical study report also provided results for several subgroups unavailable elsewhere. For HCV and COPD, additional outcome data were obtained from the EMA European Public Assessment Report (EPAR) and the FDA, respectively, including data on subgroups and mortality. We conclude that data from these grey literature sources have the potential to influence results of systematic reviews and NMAs, and may thus have implications for healthcare decisions. However, it is important to consider carefully the availability, reliability and consequent usability of these data sources in systematic reviews and NMAs.

Background

Systematic reviews and evidence-based medicine form the foundation of decision-making for healthcare agencies, making the robustness of the evidence base paramount.1–4 Where direct randomised evidence between all relevant comparators is limited or unavailable, network meta-analysis (NMA) is increasingly being used to inform healthcare decision-making.5 Feasibility of an NMA is determined by the presence of a connected network and the comparability of the data.6

It is rare that all data for all end points of interest are available or reported in peer-reviewed publications, and gaps in the available data can preclude evidence synthesis due to the absence of parameters to inform or connect evidence networks.7 8

In conducting a systematic review, peer-reviewed publications and (non-peer-reviewed) conference proceedings are searched to identify studies relevant to the research question.1 2 When such evidence is limited, inclusion of data from other sources can be important.9 10

Owing to the increased transparency in clinical trial reporting mandated by a number of authorities, additional sources of data are becoming more accessible, for example, through publicly accessible websites of clinical trial registries. The US Food and Drug Administration (FDA) requires all interventional studies of all drugs, biologics and devices, falling within its jurisdiction to be registered on ClinicalTrials.gov, and the European Medicines Agency (EMA) stipulates that all trials carried out in the European Union are registered in the European Clinical Trials database (EudraCT). On 21 July 2014, it became mandatory for sponsors to post summary information on the EudraCT, including trial design, objective(s), baseline characteristics and end point data, which are made available to the public.11 12

As part of regulatory submissions, the EMA and the FDA publish publically available documents that provide selected trial results used to inform these submissions. For example, the EMA’s European Public Assessment Report (EPAR) provides information on the medicine as well as the EMA assessment, and the FDA’s preapproval and postmarketing documents report limited clinical trial information. Both agencies may also request additional data on end points that are not otherwise reported or published should they feel the study sponsor has not provided enough data to inform the regulatory decision.11 13 Redacted versions of clinical study reports, the most detailed source of data for clinical trials, are sometimes made available by trial sponsors through the sponsor websites. However, these websites are often not user-friendly and finding the clinical study report of interest is tricky. In addition, if the report is available, these documents are long and challenging to navigate.

Thus, systematic reviewers have an increasing number of sources available to populate data extraction forms appropriately and completely, in order to have all available information pertinent to the assessment and conduct of an NMA. We illustrate, through the use of case studies, the importance of considering additional data sources for clinical trial data beyond peer-reviewed publications, such as clinical trials registries and clinical study reports. Failure to do so may result in incomplete data and preclude or potentially bias analyses.

Methods

Case reports 1 and 2: reporting in peer-reviewed literature versus clinical trials registries and clinical study reports

We selected two examples of clinical trials, based on our experience in systematic reviews, where we had previously observed differences in reporting of efficacy results between peer-reviewed publications and clinical trial registries. GlaxoSmithKline (GSK) is developing a new melanoma therapeutic, GS-117, which targets the immune checkpoint receptor PD-L1. In February 2014, the results of a phase 1 dose-escalation study of GS-117 in patients with advanced melanoma were reported in the New England Journal of Medicine, which was the only source of efficacy data.9 10

In the absence of direct evidence between GS-117 and another agent, the comparator data were obtained from the phase 3 study of pembrolizumab (Keytruda; Merck) in advanced melanoma.15 While both studies were conducted in the melanoma setting, the pembrolizumab study differed in several important respects, including melanoma stage, patient population, survival end point and the fact that Keytruda was the first-in-class PD-1 inhibitor. These differences may have implications for the interpretation of results from the GS-117 study, and the information needed to conduct a NMA, which was not present in the published version of the pembrolizumab study. It was also noted that pembrolizumab was approved on the basis of positive results from a separate phase 2 study in advanced melanoma, the results of which are not publicly available.

As a result of the increased transparency in clinical trial reporting mandated by a number of authorities, such as the EMA and the FDA, it is now possible to access additional outcome data from peer-reviewed publications, clinical study reports and regulatory proceedings.6 11 12

For melanoma, the phase 3 study of pembrolizumab was registered at ClinicalTrials.gov on 15 October 2014 and met the criteria for registration on the basis of the New England Journal of Medicine publication. At the time of writing, the study reports for both GS-117 and pembrolizumab were not available online, but were due to be posted on ClinicalTrials.gov imminently.

It is uncertain whether the additional data from the EMA European Public Assessment Report (EPAR) will provide results for several subgroups that are not otherwise reported in the peer-reviewed publications: subgroup data and additional efficacy end points. The EMA European Public Assessment Report (EPAR) provides information on the medicine as well as the EMA assessment, and the FDA’s preapproval and postmarketing documents report limited clinical trial information. Both agencies may also request additional data on end points that are not otherwise reported or published should they feel the study sponsor has not provided enough data to inform the regulatory decision.11 13

As part of regulatory submissions, the EMA and the FDA publish publically available documents that provide selected trial results used to inform these submissions. For example, the EMA’s European Public Assessment Report (EPAR) provides information on the medicine as well as the EMA assessment, and the FDA’s preapproval and postmarketing documents report limited clinical trial information. Both agencies may also request additional data on end points that are not otherwise reported or published should they feel the study sponsor has not provided enough data to inform the regulatory decision.11 13

Redacted versions of clinical study reports, the most detailed source of data for clinical trials, are sometimes made available by trial sponsors through the sponsor websites. However, these websites are often not user-friendly and finding the clinical study report of interest is tricky. In addition, if the report is available, these documents are long and challenging to navigate.

Thus, systematic reviewers have an increasing number of sources available to populate data extraction forms appropriately and completely, in order to have all available information pertinent to the assessment and conduct of an NMA. We illustrate, through the use of case studies, the importance of considering additional data sources for clinical trial data beyond peer-reviewed publications, such as clinical trials registries and clinical study reports. Failure to do so may result in incomplete data and preclude or potentially bias analyses.

Methods

Case reports 1 and 2: reporting in peer-reviewed literature versus clinical trials registries and clinical study reports

We selected two examples of clinical trials, based on our experience in systematic reviews, where we had previously observed differences in reporting of efficacy results between peer-reviewed publications and clinical
Case reports 3 and 4: augmenting the evidence base with data from regulatory authorities

We evaluated how data from regulatory authorities added to the evidence base for systematic reviews and NMAs. To illustrate this, we used the example of the impact of data from the EMA on NMA in chronic obstructive pulmonary disease (COPD). In each case study, differences between the sources were reported and their potential impact on conducting systematic reviews and NMAs was assessed.

All data were extracted by a single reviewer and the extractions were independently verified by a second reviewer.

Results and discussion

Case report 1: reporting in peer-reviewed literature versus clinical trials registries and clinical study reports—melanoma

The primary peer-reviewed publication for METRIC is Flaherty et al. A secondary publication reports a quality-of-life analysis only and is not discussed further here. We identified the associated ClinicalTrials.gov webpage using the NCT01245062 trial identifier and the key outcomes investigated (this trial was not registered on EudraCT). We obtained a redacted version of the clinical study report from the GSK clinical study register (http://www.gsk-clinicalstudyregister.com). Aggregate data were not redacted and all end points from the trial were available.

Table 1 summarises the efficacy outcomes reported in each data source. An important difference was in the reporting of end point by treatment line, whereas Flaherty et al reported on the intention-to-treat (ITT) population (including patients who were chemotherapy naïve (first-line) and those who were chemotherapy experienced (second-line)), ClinicalTrials.gov reported progression-free survival (PFS) separately for first-line and second-line patients, data particularly useful in systematic reviews, and NMAs investigating treatments in melanoma for a specific treatment line. Furthermore, Flaherty et al reported results only for the ITT population, whereas ClinicalTrials.gov reported outcomes for several subpopulations including presence of brain metastases (table 1).

We found further discrepancies: Flaherty et al reported hazard ratios (HRs) for PFS for the subpopulations, but did not report median PFS. In contrast, ClinicalTrials.gov reported median PFS for these subpopulations but did not report HRs. Different presentations of data may consequently inhibit or complicate evidence syntheses.

While all study outcomes considered in this example were available from the redacted clinical study report, as this consisted of 2236 pages, considerable time was needed to source these data. Additional end points were also available from the clinical study report with several results reported for multiple subgroups. However, due to the limited benefit to this case study and the extensive nature of the document, these additional end points were not extracted.

Table 1 Comparison of reporting between sources in METRIC

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Population</th>
<th>Flaherty et al</th>
<th>ClinicalTrials.gov</th>
<th>Clinical study report</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFS (median)</td>
<td>BRAF V600E +ve participants without a history of brain metastases</td>
<td>✓ (HR available)</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>All participants</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>BRAF V600E +ve participants without a history of brain metastases and without prior chemotherapy</td>
<td>✓ (HR available)</td>
<td>✓ (HR not available)</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>BRAF V600E +ve participants without a history of brain metastases and with prior chemotherapy</td>
<td>✓ (HR available)</td>
<td>✓ (HR not available)</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>OS (median)</td>
<td>All participants</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>BRAF V600E +ve participants without a history of brain metastases</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>ORR</td>
<td>BRAF V600E +ve participants without a history of brain metastases</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>All participants</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>CR/PR</td>
<td>BRAF V600E +ve participants</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>BRAF V600K +ve participants</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>DOR (median)</td>
<td>Number of participants with OR following crossover to trametinib</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>BRAF V600 +ve participants without a prior history of brain metastases</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>All participants</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>All responders following crossover to trametinib</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>PFS following crossover to trametinib</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

CR, complete response; DOR, duration of response; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response.
Case report 2: reporting in peer-reviewed literature versus clinical trials registries and clinical study reports—JIA

Key outcomes for the CHERISH trial were identified from the peer-reviewed publication and from ClinicalTrials.gov again using the unique study identifier NCT00988221 (Table 2). No results were available from the EudraCT entry, and the clinical study report was not publicly available from the Roche website.

All results reported in Brunner et al were available through ClinicalTrials.gov, but several outcomes available on ClinicalTrials.gov were not reported in the peer-reviewed publication.

A major difference was that ClinicalTrials.gov reported 104-week outcome data, whereas the latest time point reported by Brunner et al was week 40. Longer follow-up data are important as they permit assessment of long-term efficacy and safety; this is particularly true for trials in which survival is a measure of efficacy. Reporting multiple time points can also be informative when conducting longitudinal NMA.

Efficacy was assessed using the JIA American College of Rheumatology (ACR) response criteria, within which there are JIA core response variables and JIA-ACR 30/50/70/90 responses (achieved if patients have a 30/50/70/90% or greater improvement in three or more of the JIA-core response variables (CRVs)). Brunner et al reported only the proportion of patients achieving the core response variables at week 16, whereas ClinicalTrials.gov reported, in addition, change in each JIA core response variables from baseline to week 16. Furthermore, ClinicalTrials.gov reported all efficacy outcomes at week 104, none of which were reported in the peer-reviewed publication.

Case report 3: augmenting the evidence base with data from regulatory authorities—HCV

To address the lack of head-to-head studies comparing simeprevir with boceprevir or telaprevir in treatment-naïve HCV patients, our group indirectly compared the efficacy and safety of these regimens in an NMA. Results were presented at the American Association for the Study of Liver Disease 2013 meeting including a subgroup analysis to determine the effect of baseline METAVIR score on sustained virological response to treatment. Although METAVIR subgroup data for telaprevir were available in the primary publication, those for boceprevir were not; these latter were reported in the EMA EPAR (Table 3). Without the addition of these EPAR data, an indirect comparison of simeprevir versus telaprevir and boceprevir, in accordance with the licensing in patients with specific stages of fibrosis would not have been possible.

Case report 4: augmenting the evidence base with data from regulatory authorities—COPD

Although mortality is an increasingly important consideration in COPD, publications of trial data do not always report on-trial mortality. During a review by our research group, we identified Dong et al which conducted a systematic review and NMA of RCTs in COPD reporting overall death or cardiovascular death. Overall and cardiovascular mortality data were unavailable from four peer-reviewed publications, but these data were sourced from the FDA website allowing a more comprehensive review than would have been possible using peer-reviewed publications only (Table 4).

Table 2

<table>
<thead>
<tr>
<th>Outcomes reported</th>
<th>Brunner et al ClinicalTrials.gov.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with JIA ACR30 flare (weeks 16–40) (%)</td>
<td>✓</td>
</tr>
<tr>
<td>Patients achieving JIA ACR 30/50/70/90 responses (baseline to week 16) (%)</td>
<td>✓</td>
</tr>
<tr>
<td>All JIA core response variables at week 16</td>
<td>×</td>
</tr>
<tr>
<td>Patients achieving JIA ACR 30/50/70/90 responses (week 40) (%)</td>
<td>✓</td>
</tr>
</tbody>
</table>

Table 3

<table>
<thead>
<tr>
<th>Outcome of interest</th>
<th>Availability of end point of interest</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Peer-reviewed publication</td>
</tr>
<tr>
<td>METAVIR score F0–F2</td>
<td>✓</td>
</tr>
<tr>
<td>METAVIR score F3</td>
<td>×</td>
</tr>
<tr>
<td>METAVIR score F4</td>
<td>×</td>
</tr>
</tbody>
</table>

F0–F4= liver fibrosis severity scale.

EPAR, European Public Assessment Report.
Limited availability of end point data is a constraint of many systematic reviews and meta-analyses. In the context of healthcare decision-making, it is vital to have all available data to make the best informed decisions. Where evidence is lacking from conventional peer-reviewed sources, efforts should be made to retrieve data from alternative sources in order of usability.

Health technology assessment (HTA) agencies expect evidence submissions to incorporate all the available, relevant evidence and responsibility lies with the systematic reviewer and meta-analyst to ensure this evidence is captured.

Through our examples, we show differences exist in the level of reporting between peer-reviewed publications and the corresponding clinical trials registries webpage, the website of regulatory agencies and also the trial clinical study report where available. Arguably the most important difference identified in reporting was end point availability by previous therapies for the METRIC trial. The peer-reviewed publication reported PFS results for the ITT population regardless of their previous exposure to chemotherapy. ClinicalTrials.gov reported results by chemotherapy status: naïve or experienced. In the current landscape of oncology drug approval, where products are often licensed for a specific set of patients based on their previous treatment exposure, these results could impact on any systematic reviews or NMAs in melanoma. As the EMA and FDA now require all trials within their jurisdiction to be registered on either EudraCT or ClinicalTrials.gov, results will increasingly be made available through these registries.

Schroll et al recently investigated the accessibility and usefulness of data from EMA and FDA reports and concluded while FDA reports provide more substantial outcome data, they are more difficult to navigate than EMA reports, are often considerably larger and lack standardisation in reporting.

Locating these documents on the EMA and FDA websites can be challenging; there is a need for further improvement in ease of website navigation and in clarity of reporting.

Although several authors have investigated the influence of unpublished data from FDA reports on systematic reviews and NMAs, disparity exists in the conclusions reached. MacLean et al searched for FDA reviews of new drug applications for selected non-steroidal anti-inflammatory drugs (NSAIDs) and compared these with published trial data, focussing on dyspepsia as a toxicity outcome. They found no significant difference between the published and unpublished data with respect to pooled estimates of the risk of dyspepsia. Hart et al recalculated selected meta-analyses that were conducted on trials that had unpublished FDA data available. Comparison of the summary data from reanalyses incorporating unpublished FDA data revealed increased and reduced drug efficacy in approximately equal numbers. McDonagh et al investigated Drug Effectiveness Review Project (DERP) reports, including data from FDA documents. They reported that 30 of 175 FDA reviews contained unpublished data that were used in 34 DERP reports. Conclusions were affected by the inclusion of these unpublished data in 11 of the DERP reviews, 9.6% of the total DERP reports investigated. Including unpublished data may not always influence the results of evidence syntheses, but it is apparent that the potential for it to do so exists.

Our case studies were selected based on our previous experience in systematic reviews in these disease areas. Although not systematic in our selection, these isolated examples illustrate the need to consider the additional sources of unpublished data discussed in this paper.

Conclusion

Peer-reviewed publications remain the most robust source of data for a systematic review, having long been regarded as an essential tool for assessing and improving the quality of publications, in their methodology and presentation of data. However, as limitations in the availability of data can lead to bias in systematic reviews and NMAs, potentially overestimating or underestimating treatment effects, and as data in the grey literature sources become increasingly available, these should be considered for inclusion. Nevertheless, we should bear in mind, grey literature lead to additional, sometimes substantial costs of retrieval and are not subjected to peer-review before being made publically available; thus, responsibility for the accuracy and presentation of the data lies with the sponsor.

We have discussed examples where unpublished data have informed reviews, analyses and potentially subsequent healthcare decisions. In addition, we have considered multiple sources of unpublished data and the benefit of each medium with respect to accessibility of the data and the potential to obtain additional evidence. We found that additional data could be obtained by searching these sources; however to search for and navigate all of these documents for every study in a systematic review would be unfeasible. The extensive nature of clinical study reports and the difficulties we and others have encountered in navigating regulatory websites make these sources less favourable than clinical trials registries. We believe researchers will gain the greatest benefit by considering first clinical trials registries, then FDA and EMA documents, and finally clinical study reports. We recommend researchers consider the evidence base for each research question and determine whether the benefit of searching the sources explored here outweigh the increased burden of searching and negative implications of incomplete data. Further research should investigate the consistency between peer-review publications and supplementary sources of data.
Acknowledgements The authors thank Jo Whelan and Moira Hudson for their reviewing and editing this manuscript. No funding was received for the development of this manuscript.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

References


18. GloxSmithKline. A Phase III randomized, open-label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma. November 2014. http://www.gsk-clinicalstudyregister.com/study/114267csrvtoken=1455140350.58%23%238600555e1dee84b9535ceb286571a33bc99a208a1423475e60d76e8e1search_terms=trametinib+titles+txtstudy+ids+txtstudy+type+docdocument_type+ftrecruitment+ftconditions+melanoma+compounds+ftfiled=ftcollaborators+ftgender+ftpatient+level+data+ftedge_from+ftedge+from+type+ftedge+to+type+ftftfirst+receive_from+ftfirst+receive_to+ftlast+updated_from+ftlast+updated_to+ftcountry+ftstudy+ftsearch+ftcsrv


31. EMA. European Medicines Agency policy on publication of clinical data for medicinal products for human use. 2014.


